Profitability Metrics

Gross Margin
39.93%
Operating Margin
16.00%
Net Margin
13.99%

Efficiency Metrics

Revenue per Expense Ratio
1.19
R&D as % of Revenue
3.12%

Earnings Quality

EBITDA Margin
26.12%
Income Tax Rate
4.51%
EPS
15.5300000000

Balance Sheet Analysis

Current Ratio
1.75
Cash Ratio
0.58
Working Capital
$10.58B
Debt to Equity
0.75
Debt to Assets
35.37%
Equity Ratio
47.34%

Cash Flow Analysis

Operating Cash Flow Ratio
19.61%
Free Cash Flow Ratio
16.16%
CapEx to Revenue
3.45%
Dividends Paid
$523.00M
Stock Buybacks
$3.00B
Total Shareholder Returns
$3.52B
Cash Position Change
-5.38%

Key Takeaways (2023 FY)

  • Revenue declined by 4.5819881999332%, indicating potential market challenges
  • Increased dividend payments by 16.73%

Detailed Growth Metrics

Core Performance

Revenue
-4.58%
Net Income
-13.74%
EPS
-12.41%
Operating Income
-18.28%

Operational Efficiency

R&D Expenses
-9.11%
SG&A Expenses
18.49%
Operating Cash Flow
-8.17%
Free Cash Flow
0.23%

Balance Sheet Health

Assets
1.62%
Debt
1.24%
Book Value per Share
7.75%
Inventory
-9.69%

Shareholder Returns

Dividends per Share
16.73%
Shares Outstanding
-1.53%

Long Term Trends

3Y Revenue/Share
36.47%
5Y Revenue/Share
83.24%
3Y Dividend/Share
59.21%
5Y Dividend/Share
104.77%